Genentech Reports Results of Xofluza (baloxavir marboxil) in P-III MINISTONE-2 Study for Influenza in Children
Shots:
- The P-III MINISTONE-2 (NCT03629184) study involves assessing of Xofluza vs Oseltamivir in children with an influenza infection aged b\w 1 to ≤12yrs. confirmed by rapid influenza diagnostic test/ influenza symptoms
- The P-III MINISTONE-2 study resulted in meeting its 1EPs demonstrating reduction in duration of flu symptoms including fever and is well tolerated in children with flu
- Xofluza is an oral therapy approved in the US & Japan in treating influenza in children- being evaluated in P-III MINISTONE-1 study for flu in children < 1yr. with its expected FDA’s sNDA approval on Nov 04- 2019
Click here to read full press release/ article | Ref: Genentech | Image: Commercial Cafe
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com